image
Healthcare - Medical - Devices - NASDAQ - US
$ 2.21
-3.91 %
$ 113 M
Market Cap
-2.15
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SGHT stock under the worst case scenario is HIDDEN Compared to the current market price of 2.21 USD, Sight Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SGHT stock under the base case scenario is HIDDEN Compared to the current market price of 2.21 USD, Sight Sciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one SGHT stock under the best case scenario is HIDDEN Compared to the current market price of 2.21 USD, Sight Sciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SGHT

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
79.9 M REVENUE
-1.47%
-50.5 M OPERATING INCOME
11.77%
-51.5 M NET INCOME
7.27%
-22.4 M OPERATING CASH FLOW
52.63%
-385 K INVESTING CASH FLOW
51.33%
4.96 M FINANCING CASH FLOW
349.64%
19.1 M REVENUE
-5.37%
-11.9 M OPERATING INCOME
-6.23%
-11.8 M NET INCOME
-7.05%
-3.46 M OPERATING CASH FLOW
-576.50%
-137 K INVESTING CASH FLOW
-168.63%
5.39 M FINANCING CASH FLOW
3426.54%
Balance Sheet Sight Sciences, Inc.
image
Current Assets 140 M
Cash & Short-Term Investments 120 M
Receivables 10.8 M
Other Current Assets 8.63 M
Non-Current Assets 3.06 M
Long-Term Investments 0
PP&E 2.52 M
Other Non-Current Assets 550 K
84.26 %7.55 %6.04 %Total Assets$142.8m
Current Liabilities 15.5 M
Accounts Payable 1.69 M
Short-Term Debt 533 K
Other Current Liabilities 13.2 M
Non-Current Liabilities 39.8 M
Long-Term Debt 39.8 M
Other Non-Current Liabilities 19 K
3.06 %23.94 %72.00 %Total Liabilities$55.3m
EFFICIENCY
Earnings Waterfall Sight Sciences, Inc.
image
Revenue 79.9 M
Cost Of Revenue 11.6 M
Gross Profit 68.3 M
Operating Expenses 119 M
Operating Income -50.5 M
Other Expenses 975 K
Net Income -51.5 M
80m80m60m60m40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)80m(12m)68m(119m)(51m)(975k)(52m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
85.50% GROSS MARGIN
85.50%
-63.27% OPERATING MARGIN
-63.27%
-64.49% NET MARGIN
-64.49%
-58.85% ROE
-58.85%
-36.06% ROA
-36.06%
-39.69% ROIC
-39.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Sight Sciences, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)20192019202020202021202120222022202320232024202420252025
Net Income -51.5 M
Depreciation & Amortization 712 K
Capital Expenditures -385 K
Stock-Based Compensation 17.1 M
Change in Working Capital 9 M
Others 5.86 M
Free Cash Flow -22.7 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Sight Sciences, Inc.
image
Wall Street analysts predict an average 1-year price target for SGHT of $7 , with forecasts ranging from a low of $4 to a high of $10 .
SGHT Lowest Price Target Wall Street Target
4 USD 81.00%
SGHT Average Price Target Wall Street Target
7 USD 216.74%
SGHT Highest Price Target Wall Street Target
10 USD 352.49%
Price
Max Price Target
Min Price Target
Average Price Target
10109988776655443322May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership Sight Sciences, Inc.
image
Sold
0-3 MONTHS
148 K USD 5
3-6 MONTHS
2.54 M USD 6
6-9 MONTHS
452 K USD 6
9-12 MONTHS
290 K USD 5
Bought
53.2 K USD 1
0-3 MONTHS
2.12 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. globenewswire.com - 3 weeks ago
Sight Sciences, Inc. (SGHT) Q4 2024 Earnings Conference Call Transcript Sight Sciences, Inc. (NASDAQ:SGHT ) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ET Company Participants Philip Trip Taylor - IR Paul Badawi - Co-Founder & CEO Alison Bauerlein - CFO Matt Link - Chief Commercial Officer Conference Call Participants Danielle Antalffy - UBS Tom Stephan - Stifel Frank Takkinen - Lake Street Capital Markets David Saxon - Needham & Company Phil Dantoin - Piper Sandler Macauley Kilbane - William Blair Operator Hello, and welcome to the Sight Sciences Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 1 month ago
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 month ago
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.22 per share a year ago. zacks.com - 1 month ago
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. globenewswire.com - 1 month ago
Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know Sight Sciences (SGHT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System globenewswire.com - 1 month ago
Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 5, 2025. globenewswire.com - 2 months ago
Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day, in New York, NY. globenewswire.com - 2 months ago
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options Budget impact analysis published in the Expert Review of Ophthalmology journal Budget impact analysis published in the Expert Review of Ophthalmology journal globenewswire.com - 4 months ago
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Piper Sandler 36th Annual Healthcare Conference, in New York, NY. globenewswire.com - 5 months ago
Sight Sciences, Inc. (SGHT) Q3 2024 Earnings Call Transcript Sight Sciences, Inc. (NASDAQ:SGHT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder & Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matt Link - Chief Commercial Officer Conference Call Participants Macauley Kilbane - William Blair Phil Dantoin - Piper Sandler Nelson Cox - Lake Street Capital Markets Tom Stephan - Stifel Operator Thank you for standing by. My name is Janine, I will be your conference operator for today. seekingalpha.com - 5 months ago
8. Profile Summary

Sight Sciences, Inc. SGHT

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 113 M
Dividend Yield 0.00%
Description Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Contact 4040 Campbell Avenue, Menlo Park, CA, 94025 https://www.sightsciences.com
IPO Date July 15, 2021
Employees 216
Officers Dr. Reay H. Brown M.D. Chief Medical Officer Mr. Brenton Taylor Executive Vice President of Operations Mr. Paul Badawi Co-Founder, President, Chief Executive Officer & Director Mr. Stephen B. Thau J.D. Secretary Dr. David Badawi M.D. Co-Founder, Chief Technology Officer & Director Dr. Manohar K. Raheja Ph.D. Executive Vice President of Research & Development Mr. Jeremy B. Hayden J.D. Chief Legal Officer Mr. Steve R. Tamayo Jr. Vice President and Chief Ethics & Compliance Officer Ms. Alison Perry Bauerlein Chief Financial Officer & Treasurer Mr. Matthew W. Link Chief Commercial Officer